Hämato-Onkologische Schwerpunktpraxis am Klinikum Aschaffenburg
- Address
- Am Hasenkopf 1, 63739 Aschaffenburg, Germany
Oncology in Neoplasms
At the Hämato-Onkologische Schwerpunktpraxis am Klinikum Aschaffenburg, clinical research focuses on cancers across the oncology spectrum, with studies centered on advanced and metastatic solid tumors. The trials are designed to explore better treatment options and improve patient outcomes in everyday cancer care.
- Metastatic non-small cell lung carcinoma and extensive-stage small-cell lung carcinoma
- Advanced or unresectable hepatocellular carcinoma
- Metastatic colorectal cancer and resected stage IIB-IIIB non-small cell lung carcinoma
The research includes both treatment-comparison studies and digital health initiatives, aiming to evaluate which cancer therapies work best and how remote monitoring tools may support symptom management and care delivery.
Therapy optimization in metastatic cancer
One area of research examines metastatic colorectal cancer, comparing established treatment combinations to determine which approach offers stronger effectiveness in first-line care. This reflects a broader effort to refine therapy choices for patients with advanced cancer.
- Comparing trifluridine/tipiracil plus panitumumab versus bevacizumab
- Evaluating treatment effectiveness in advanced colorectal cancer
These studies are focused on improving how clinicians select and sequence cancer treatments, with the goal of extending disease control and supporting better patient outcomes.
Digital health and remote care in oncology
Another research theme explores digital tools for people receiving systemic cancer treatment, including patients with non-small cell lung carcinoma and hepatocellular carcinoma. The purpose is to assess whether digital monitoring can improve symptom tracking and make treatment support more accessible.
- Testing digital patient monitoring for symptom interference and patient support
- Assessing home-based use of subcutaneous immunotherapy with digital follow-up
- Supporting care for patients receiving systemic cancer treatment
This work combines oncology with digital health solutions, reflecting interest in more flexible care models that may ease the burden of frequent clinic visits while maintaining close clinical oversight.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 1 by active trials.
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Hämato-Onkologische Schwerpunktpraxis am Klinikum Aschaffenburg
lock Showing 1 of 2 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Evaluation of Atezolizumab and Digital Health Solutions on Health Outcomes in Metastatic and Early-Stage Lung and Hepatocellular Carcinomas | F. Hoffmann-La Roche AG | Phase IV | Not Recruiting | Feb 2023 | Jun 2024 |
IMP list
lock Showing 1 of 5 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Atezolizumab | 1 | Unknown | 2023-02-02 | 2023-02-02 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.